Waters Corporation Raises Full-Year Guidance After Strong Q2 Performance — Waters Corporation

Event summary

Waters Corporation reported $1.645 billion in total revenue for Q2 2026, surpassing guidance driven by broad-based outperformance across organic revenue and acquired businesses.
Organic revenue grew 7% as reported and 9% in constant currency, with the Analytical Sciences Division delivering 8% instrument growth and double-digit chemistry consumables growth.
Biosciences and Diagnostic Solutions revenue exceeded guidance by $15 million, growing 4% on a prior year comparable basis.
The company raised its full-year 2026 organic constant currency revenue growth guidance to 7-9%, with adjusted EPS expected to grow 10-12%.
GAAP EPS was ($1.39) due to acquisition-related purchase accounting charges, while adjusted EPS grew 3% to $3.05.

The big picture

Waters Corporation's strong Q2 performance and raised guidance reflect a broader market recovery in life sciences and diagnostics. The company's strategic focus on integrating acquired businesses and executing operational improvements positions it for sustained growth, despite challenges from foreign exchange translation. The scale of its portfolio and installed base provides a competitive advantage in high-volume testing environments.

What we're watching

Integration Momentum: The pace at which Waters Corporation integrates the acquired Biosciences and Diagnostic Solutions businesses will determine the realization of anticipated synergies.
Market Recovery: Whether the broader market recovery in Pharma and A&G end markets can be sustained across additional customer segments.
Cost Actions: How early cost actions will continue to offset unfavorable foreign exchange translation impacts on profitability.